Hereditary Angioedema Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Hereditary Angioedema market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Takeda, Shire, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring

[Nevada, United States] - DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Hereditary Angioedema, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Hereditary Angioedema Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Hereditary Angioedema Market Report:
• The Hereditary Angioedema market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Intellia Therapeutics announced that their HAELO: a Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study will Evaluate the Efficacy and Safety of NTLA-2002 in Participants with Hereditary Angioedema (HAE)
• In October, 2024: Astria Therapeutics, Inc. announced their Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients with Hereditary Angioedema (The ALPHA-SOLAR Trial)
• In October, 2024: CSL Behring announced an Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
• In October, 2024: Ionis Pharmaceuticals, Inc. announced a Phase 3, multi-center, double-blind, randomized, placebo-controlled study of donidalorsen in up to 84 participants. Participants will be randomized in a 2:1 ratio to Cohort A (donidalorsen or placebo every 4 weeks) or Cohort B (donidalorsen or placebo every 8 weeks), respectively. Within each Cohort, participants will be randomized in a 3:1 ratio to receive donidalorsen or matching-placebo.
• In October, 2024: KalVista Pharmaceuticals, Ltd. announced an Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with Hereditary Angioedema Type I or II
• As per the DelveInsight's assessment, the total diagnosed prevalent cases of HAE in the 7MM in2023was13,900 which is expected to increase by 2034, at a considerable CAGR
• In EU4 and the UK region, the UK had the highest diagnosed prevalent population of HAE, with nearly1,400cases, followed by Germany, which had 1,300 diagnosed prevalent population in2023. On the other hand,Spain and Italy had the lowest number of diagnosed prevalent populations each having less than 1000casesin 2023.
• As per Delveinsight's analysis, a higher percentage ofdiagnosed prevalent cases were observed in the age group17-65 years in the 7MM i.e., 11,000in 2023, which areanticipated to rise during the forecast period (2024-2034).
• Key Hereditary Angioedema Companies are as follows: Takeda, Shire, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring
• Key Hereditary Angioedema Therapies are as follow: Takhzyro, Firazyr, Cinryze, Kalbitor, Haegarda, Berinert, Ruconest, BCX7353, IONIS-PKK-LRx, KVD900, CSL312
• Launching multiple stage Hereditary Angioedema pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Hereditary Angioedema market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hereditary Angioedema Overview:
Hereditary angioedema (HAE) is a rare hereditary condition that manifests as recurring incidents of localized subcutaneous (SC) or mucosal edema, most frequently affecting the skin, intestines, upper respiratory system, and oropharynx.

Hereditary Angioedema Epidemiology Segmentation:
The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Hereditary Angioedema Total Diagnosed Prevalent Cases
• Hereditary Angioedema Type-specific Diagnosed Prevalent Cases
• Hereditary Angioedema Gender-specific Diagnosed Cases
• Hereditary Angioedema Age-specific Diagnosed Prevalent Cases

For more information about Hereditary Angioedema companies working in the treatment market, visit https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hereditary Angioedema Market Insights
Hereditary Angioedema is a rare disorder resulting from decreased functional levels of C1-INH that manifests as periodic episodes of localized edema, which can be extremely painful, debilitating, and even fatal if the swelling affects the larynx. While there is no cure for HAE, there are many ways to prevent or subdue swelling attacks. SeveralHAE-specific agents are currently available, including attenuated androgens; while regional availability,regulatory approvals, and/or cost barriers may prevent access to some of these medications, other less proven therapies may have a role, including antifibrinolytics and fresh frozen plasma.

Hereditary Angioedema Drugs Uptake
• TAKHZYRO (lanadelumab, Takeda) is a newly-developed monoclonal antibody approved for long-termprophylaxis in HAE patients aged 12 and older. It inhibits plasma kallikrein, preventing the formation of BK and,therefore, decreasing the risk of developing angioedema.
• CINRYZE (Takeda) is an IV human plasma-derived C1-INH approved for patients aged 6 and older. CINRYZErequires IV administration every 3-4 days, and some patients may need higher than typical doses to achieve a reduction in attacks.
• HAEGARDA (CSL Behring) was approved for long-term prophylaxis for adults and adolescents to fulfill this unmet need. It is a human plasma-derived C1-INH, taken twice weekly as an SC injection. HAEGARDA as a prophylaxis treatment is more effective than CINRYZE and attracts a greater number of patients due to the ease of administration.
• ORLADEYO (BioCryst Pharmaceuticals) is an oral, once-daily inhibitor of plasma kallikrein for prophylaxis ofHAE attacks in adults and adolescents ≥12 years. It is a prophylactic drug that gives patients an easy route of administration.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hereditary Angioedema Therapies and Key Companies:
• Takhzyro: Takeda
• Firazyr: Shire/Takeda
• Cinryze: Shire/Takeda
• Kalbitor: Shire/Takeda
• Haegarda: CSL Behring
• Berinert: CSL Behring
• Ruconest: Pharming Group
• BCX7353: BioCryst Pharmaceuticals
• IONIS-PKK-LRx: Ionis Pharmaceuticals
• KVD900: KalVista Pharmaceuticals
• CSL312: CSL Behring

Hereditary Angioedema Epidemiology:
It is known that genetic mutation passes on from parents to a subsequent generation. HAE, a hereditary disease,has a 50% chance to pass on to the next generation, which might eventually increase the HAE therapeuticmarket. As per the DelveInsight's assessment, the total diagnosed prevalent cases of HAE in the 7MM in2023was13,900 which is expected to increase by 2034, at a considerable CAGR.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hereditary Angioedema Market Drivers:
• Increasing incidence of hereditary angioedema
• Rising awareness and improved diagnosis
• Advancements in targeted therapies
• Patient advocacy and education efforts

Hereditary Angioedema Market Barriers:
• High cost of treatment
• Stringent regulatory requirements
• Misdiagnosis and lack of awareness
• Limited access to treatment in some regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Hereditary Angioedema Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Hereditary Angioedema Companies: Takeda, Shire, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring
• Key Hereditary Angioedema Therapies: Takhzyro, Firazyr, Cinryze, Kalbitor, Haegarda, Berinert, Ruconest, BCX7353, IONIS-PKK-LRx, KVD900, CSL312
• Hereditary Angioedema Therapeutic Assessment: Current marketed and emerging therapies
• Hereditary Angioedema Market Dynamics: Hereditary Angioedema Market drivers and Hereditary Angioedema barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hereditary Angioedema Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Hereditary Angioedema market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Hereditary Angioedema (HAE): Market Overview at a Glance
3. Executive summary
4. Organizations
5. Epidemiology and Market Methodology
6. Treatment of Hereditary Angioedema
7. Epidemiology and Patient Population
8. Marketed Therapies
9. Emerging Therapies
10. Hereditary Angioedema: 7 Major Market Analysis
11. KOL Views
12. SWOT Analysis
13. Unmet Needs
14. Market Access and Reimbursement
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.